Teja Muralidhar Kalidindi1, Sang-Gyu Lee1, Katerina Jou1, Goutam Chakraborty2, Myrto Skafida3, Scott T Tagawa4,5, Neil H Bander5, Heiko Schoder1,3, Lisa Bodei1,3, Neeta Pandit-Taskar1,3, Jason S Lewis1,3,6, Steven M Larson1,3,6, Joseph R Osborne7, Naga Vara Kishore Pillarsetty8,9. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, MSKCC Zuckerman Building, 417 E 68th St, New York, NY, 10065, USA. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Radiology, Weill Cornell Medicine, New York, NY, USA. 4. Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Urology, Weill Cornell Medicine, New York, NY, USA. 6. Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, USA. 7. Department of Radiology, Weill Cornell Medicine, New York, NY, USA. jro7001@med.cornell.edu. 8. Department of Radiology, Memorial Sloan Kettering Cancer Center, MSKCC Zuckerman Building, 417 E 68th St, New York, NY, 10065, USA. pillarsn@mskcc.org. 9. Department of Radiology, Weill Cornell Medicine, New York, NY, USA. pillarsn@mskcc.org.
Abstract
PURPOSE: Peptide-based prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT) agent [177Lu]-PSMA-617 has emerged as leading TRT candidate for treatment of castration-resistant prostate cancer (mCRPC). [177Lu]-PSMA-617 and other small molecule-based PSMA ligands have shown efficacy in reducing the tumor burden in mCRPC patients but irradiation to the salivary gland and kidneys is a concern and dose-limiting factor. Therefore, methods to reduce non-target organ toxicity are needed to safely treat patients and preserve their quality of life. Herein, we report that addition of cold PSMA ligand PSMA-11 can aid in reducing the uptake of [177Lu]-PSMA-617 in the salivary glands and kidneys. METHODS: Groups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [177Lu]-PSMA-617 along with 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 and biodistribution studies were performed at 1 h. RESULTS: Biodistribution studies at 1 h post-administration revealed that [177Lu]-PSMA-617 uptake in PC3-PIP tumors was 21.71 ± 6.13, 18.7 ± 2.03, 26.44 ± 2.94, 16.21 ± 3.5, 13.52 ± 3.68, and 12.03 ± 1.96 %ID/g when 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 were added, respectively. Corresponding uptake values in kidney were 123.14 ± 52.52, 132.31 ± 47.4, 84.29 ± 78.25, 2.12 ± 1.88, 1.16 ± 0.36, and 0.64 ± 0.23 %ID/g, respectively. Corresponding salivary gland uptake values were 0.48 ± 0.11, 0.45 ± 0.15, 0.38 ± 0.3, 0.08 ± 0.03, 0.09 ± 0.07, and 0.05 ± 0.02 % ID/g, respectively. CONCLUSION: The uptake of [177Lu]-PSMA-617 in the salivary gland and kidney can be substantially reduced without significantly impacting tumor uptake by adding cold PSMA-11.
PURPOSE: Peptide-based prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT) agent [177Lu]-PSMA-617 has emerged as leading TRT candidate for treatment of castration-resistant prostate cancer (mCRPC). [177Lu]-PSMA-617 and other small molecule-based PSMA ligands have shown efficacy in reducing the tumor burden in mCRPC patients but irradiation to the salivary gland and kidneys is a concern and dose-limiting factor. Therefore, methods to reduce non-target organ toxicity are needed to safely treat patients and preserve their quality of life. Herein, we report that addition of cold PSMA ligand PSMA-11 can aid in reducing the uptake of [177Lu]-PSMA-617 in the salivary glands and kidneys. METHODS: Groups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [177Lu]-PSMA-617 along with 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 and biodistribution studies were performed at 1 h. RESULTS: Biodistribution studies at 1 h post-administration revealed that [177Lu]-PSMA-617 uptake in PC3-PIP tumors was 21.71 ± 6.13, 18.7 ± 2.03, 26.44 ± 2.94, 16.21 ± 3.5, 13.52 ± 3.68, and 12.03 ± 1.96 %ID/g when 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 were added, respectively. Corresponding uptake values in kidney were 123.14 ± 52.52, 132.31 ± 47.4, 84.29 ± 78.25, 2.12 ± 1.88, 1.16 ± 0.36, and 0.64 ± 0.23 %ID/g, respectively. Corresponding salivary gland uptake values were 0.48 ± 0.11, 0.45 ± 0.15, 0.38 ± 0.3, 0.08 ± 0.03, 0.09 ± 0.07, and 0.05 ± 0.02 % ID/g, respectively. CONCLUSION: The uptake of [177Lu]-PSMA-617 in the salivary gland and kidney can be substantially reduced without significantly impacting tumor uptake by adding cold PSMA-11.
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris Journal: Clin Cancer Res Date: 2015-07-14 Impact factor: 12.531
Authors: Michael J Evans; Peter M Smith-Jones; John Wongvipat; Vincent Navarro; Sae Kim; Neil H Bander; Steven M Larson; Charles L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2011-05-23 Impact factor: 11.205
Authors: Samuel R Denmeade; Lori J Sokoll; Susan Dalrymple; D Marc Rosen; Alyssa M Gady; Debra Bruzek; Rebecca M Ricklis; John T Isaacs Journal: Prostate Date: 2003-03-01 Impact factor: 4.104
Authors: Yan Ping Yu; Douglas Landsittel; Ling Jing; Joel Nelson; Baoguo Ren; Lijun Liu; Courtney McDonald; Ryan Thomas; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich; Jian-Hua Luo Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Chaitanya R Divgi; Eze A Wills; Lawrence Schwartz; Mithat Gönen; Peter Smith-Jones; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris Journal: EJNMMI Res Date: 2015-04-29 Impact factor: 3.138
Authors: Gregory T Kennedy; Feredun S Azari; Elizabeth Bernstein; Bilal Nadeem; Ashley E Chang; Alix Segil; Neil Sullivan; Isvita Marfatia; Azra Din; Charuhas Desphande; John C Kucharczuk; Philip S Low; Sunil Singhal Journal: Mol Cancer Ther Date: 2022-04-01 Impact factor: 6.009
Authors: V Mohan; N M Bruin; M E T Tesselaar; J P de Boer; E Vegt; J J M A Hendrikx; A Al-Mamgani; J B van de Kamer; J-J Sonke; W V Vogel Journal: EJNMMI Res Date: 2021-03-12 Impact factor: 3.138
Authors: Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun Journal: Int J Mol Sci Date: 2022-01-21 Impact factor: 5.923
Authors: Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Changyu Zheng; Corrine Goldsmith; Tim Phelps; Karen Wong; Anita T Ton; Rick Pieschl; Margaret E White; Rolf Swenson; John A Chiorini; Peter L Choyke; Frank I Lin Journal: EJNMMI Res Date: 2021-07-21 Impact factor: 3.138
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236